logo

For the Inventor, By the Inventor

Hachioji, Japan

Takeshi Hara

This inventor holds 16 USPTO granted patents. Top assignees: Teijin Limited, Hidematsu Hirai, Other. Active years: 1979-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takeshi Hara. Retrieved from https://idiyas.com/inventor/takeshi-hara-weh97c4a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 100.0

Average Co-Inventor Count = 3.2

ph-index = 10

Forward Citations = 454(Granted Patents)


Location History:

  • Hachioji, both of Tokyo, JP (1984)
  • Hachioji, JP (1979 - 1991)
  • Hachiooji, JP (1992)

Company Filing History:

goldMedal16 out of 1,605 
 
Teijin Limited
 patents
silverMedal1 out of 1 
 
Hidematsu Hirai
 patent
bronzeMedal1 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1979-1992

Loading Chart...
16 patents (USPTO):Explore Patents
1. 5106955 - Process for preparation of antibody conjugates (1992-04-21),
2. 5030719 - Cytotoxic antibody conjugates and a process for preparation thereof (1991-07-09),
3. 4638049 - Antitumor protein hybrid and process for the preparation thereof (1987-01-20),
4. 4605645 - 5-fluoro-2'-deoxyuridine derivatives and a process for the preparation (1986-08-12),
5. 4543211 - Conjugate having cytotoxicity and process for the preparation thereof (1985-09-24),
6. 4507234 - Conjugate having cytotoxicity and process for the preparation thereof (1985-03-26),
7. 4487714 - Cytocidal modified immunoglobulin and process for the preparation thereof (1984-12-11),
8. 4450154 - Antitumor hybrid and process for the preparation thereof (1984-05-22),
9. 4385169 - Reactive alpha amino acid polymer (1983-05-24),
10. 4379145 - Antitumor protein hybrid and process for the preparation thereof (1983-04-05),
11. 4368149 - Protein hybrid having cytotoxicity and process for the preparation (1983-01-11),
12. 4363758 - Cytotoxic protein hybrid and process for the preparation thereof (1982-12-14),
13. 4357273 - Antitumor protein hybrid and process for the preparation thereof (1982-11-02),
14. 4350626 - Antitumor hybrid and process for the preparation thereof (1982-09-21),
15. 4347369 - 8-Hydroxy-hexahydronaphth[1',2':4,5]imidazo[2,1-b]thiazole and its (1982-08-31),

Title: The Innovative Contributions of Takeshi Hara

Introduction

Takeshi Hara is a prominent inventor based in Hachioji, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibody conjugates. With a total of 16 patents to his name, Hara's work has had a substantial impact on medical research and therapeutic applications.

Latest Patents

Among his latest patents are groundbreaking innovations such as the "Process for Preparation of Antibody Conjugates" and "Cytotoxic Antibody Conjugates and a Process for Preparation Thereof." These patents reflect his commitment to advancing the capabilities of antibody-based therapies, which are crucial in the treatment of various diseases.

Career Highlights

Throughout his career, Hara has worked with notable companies, including Teijin Limited and Hidematsu Hirai. His experience in these organizations has allowed him to refine his skills and contribute to significant projects in the biotechnology sector.

Collaborations

Hara has collaborated with esteemed colleagues such as Yasuhiko Masuho and Yoshinori Kato. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Takeshi Hara's contributions to the field of biotechnology through his patents and collaborations highlight his role as a leading inventor. His work continues to influence advancements in medical therapies, showcasing the importance of innovation in improving healthcare outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…